Zhongwu Lai

机构：AstraZeneca (Brazil), AstraZeneca (United States) · ORCID：0000-0002-1506-8222

发表论文 308 篇 · 总被引 33246 次 · h-index 40

代表论文

• Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial. (2025 · Journal of Clinical Oncology · 被引 18)
• Patterns of genomic instability in > 2000 patients with ovarian cancer across six clinical trials evaluating olaparib (2024 · Genome Medicine · 被引 16)
• An artificial intelligence-based model for prediction of clonal hematopoiesis variants in cell-free DNA samples (2025 · npj Precision Oncology · 被引 10)
• Mutational Landscape of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Association with Immune Checkpoint Inhibitor Outcomes (2025 · Clinical Cancer Research · 被引 4)
• Phenome-wide analysis of copy number variants in 470,727 UK Biobank genomes (2026 · Nature · 被引 2)
• Author Correction: CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors (2025 · Nature · 被引 2)